BMYBristol-Myers Squibb Company

$121B

Q1 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.9B+14.0% YoY

Gross Profit

$4.1B69.1% margin

Operating Income

$1.8B30.1% margin

Net Income

$1.7B28.9% margin

EPS (Diluted)

$1.04

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.2B

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$34.8B

Total Liabilities

$19.5B

Stockholders' Equity

$15.2B

Cash & Equivalents

$7.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.9B	$5.2B	+14.0%
Gross Profit	$4.1B	$3.6B	+13.5%
Operating Income	$1.8B	$1.4B	+28.0%
Net Income	$1.7B	$1.5B	+15.1%

Revenue Segments

Eliquis

$1.9B33%

Opdivo

$1.8B30%

Orencia

$640M11%

Mature Products And All Other

$487M8%

Sprycel

$459M8%

Yervoy

$384M6%

Baraclude

$141M2%

Empliciti

$83M1%

Geographic Segments

UNITED STATES

$3.4B58%

Europe

$1.5B25%

Rest Of World

$874M15%

Other Region

$117M2%

BMY Q1 2019 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena